secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001062822-25-000033
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon shareholders approve reverse stock split authorization (1:10-1:50) and increase equity plan share reserves
--------------------------------------------------------------------------------

- Shareholders approved reverse stock split at ratio 1-for-10 to 1-for-50, at board discretion before 2026 annual meeting.
- Equity incentive plan shares increased from 55M to 75M; Non-Employee Directors plan from 2M to 4M.
- Directors Raymond Debbane and Ivan H. Cheung elected with >205M and >226M votes for, respectively.
- Ernst & Young ratified as independent auditor for FY 2025.
- Advisory vote on executive compensation approved with 220.5M for, 7.9M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000033/0001062822-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000033/lxrx-20250602.htm
  HTML page:      https://secwatch.observer/filing/0001062822-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer